# A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.

Source: https://onco.cc/trials/nct07669454/  
OnCo record `nct07669454` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nuvastatic 300 in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.

## Summary

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy. is a phase 3 interventional study registered as NCT07669454 by Natureceuticals Sdn Bhd, with 250 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-10-31. Interventions recorded: Nuvastatic 300 and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07669454
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
- Sponsor: Natureceuticals Sdn Bhd
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT07669454: https://clinicaltrials.gov/study/NCT07669454

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct07669454.json